Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Shkreli Poised to Argue He Relied on Attorney’s Advice in Fraud Trial

By Andy Szal | July 20, 2016

Controversial pharmaceutical entrepreneur Martin Shkreli is likely to argue that he was acting on his attorney’s advice during his forthcoming fraud trial.

Shkreli and Evan Greebel, who served as outside counsel for Retrophin—where Shkreli was CEO—were indicted on securities and wire fraud charges late last year amid allegations that Shkreli used company stock to pay back investors that lost money in his hedge funds.

USA Today reports that Shkreli’s attorneys told a court hearing last week that their client has strong “reliance-on-counsel” claims, which would prevent the co-defendants from being tried together.

Attorneys for Shkreli added that they wouldn’t blame Greebel and stressed than their argument “doesn’t necessarily mean that either of them committed a crime.”

A trial in the case was scheduled for next June; both Shkreli and Greebel pleaded not guilty.

Shkreli first rose to prominence as one of the most visible examples of alleged price-gouging by the pharmaceutical industry.

Turing, another pharmaceutical company he founded, raised the price of the AIDS drug Daraprim from $13.50 per pill to $750 per pill—or 5,000 percent.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50